Barbara L. Parsons

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

High Impact

Research Microbiogist

NCTR primary UAMS

Also affiliated: Agricultural Research Service (1991–1992); United States Food and Drug Administration (2003–2025); Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (1982); St. John's University (1999); Institute of Cancer Research (2011); Duke University (1984–1990); University of Wisconsin–Platteville (1974); Brookhaven National Laboratory (1982); University of South Florida (1996–2014); Cold Spring Harbor Laboratory (1982–1983); Cornwall Council (2002); Barnet Hospital (2015); Yale University (2004); Cornwall College (1999–2003); Central Arkansas Veterans Healthcare System (2007); Ion Exchange (India) (1982); Beltsville Agricultural Research Center (1991–1994); Duke Medical Center (1984–1990); Duke University Hospital (1984–1990); King's College Hospital (1977); Stony Brook University (1982); Florida College (2002–2003); University of California, Berkeley (1982–2014)

Faculty Researcher

29 h-index 144 pubs 2,782 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website

OverviewAI-generated summary

Barbara L. Parsons, a Research Microbiologist at the National Center for Toxicological Research, focuses her work on genotoxicity and carcinogenicity assessment, particularly employing advanced sequencing technologies. Her research investigates the detection and interpretation of genetic mutations in the context of cancer risk. Parsons has published on the use of error-corrected next-generation sequencing (NGS) to improve the accuracy of genotoxicity testing and cancer risk assessment, highlighting its promises and challenges.

Her work includes the development and application of genomic reference samples for assessing the performance of cancer panels in detecting small genetic variants. Parsons has also explored the measurement of cancer driver mutations using CarcSeq technology in various tissues and their correlation with spontaneous neoplasia in animal models, such as rats and mice. She collaborates with several researchers at the National Center for Toxicological Research, including Meagan B. Myers, Robert H. Heflich, Binsheng Gong, and Kelly L. Harris, with whom she has co-authored multiple publications. Parsons has an h-index of 29 and has published a total of 144 papers, accumulating over 2,756 citations.

Metrics

h-index: 29
Publications: 144
Citations: 2,782

Selected Publications

Expansion of preexisting cancer driver mutant clones is induced by the genotoxic carcinogen benzo[b]fluoranthene in MutaMouse lung (2026)

Toxicological Sciences DOI OpenAlex
Tissue and Sex‐Specific Performance of a Cancer Driver Based Biomarker in <scp>rasH2</scp> ‐Tg Mice (2025)

Environmental and Molecular Mutagenesis 2 citations DOI OpenAlex
Transferability, Reproducibility and Sensitivity of Mutation Quantification by Duplex Sequencing (2025)

Environmental and Molecular Mutagenesis 6 citations DOI OpenAlex
Clonal expansion of cancer driver gene mutants investigated using advanced sequencing technologies (2024)

Mutation Research/Reviews in Mutation Research 5 citations DOI OpenAlex
Repeat treatment of organotypic airway cultures with ethyl methanesulfonate causes accumulation of somatic cell mutations without expansion of bronchial-carcinoma-specific cancer driver mutations (2024)

Mutation Research/Genetic Toxicology and Environmental Mutagenesis 4 citations DOI OpenAlex
CarcSeq detection of lorcaserin-induced clonal expansion of<i>Pik3ca</i>H1047R mutants in rat mammary tissue (2024)

Toxicological Sciences 4 citations DOI OpenAlex
<scp>Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing</scp> ( <scp>IWGT</scp> ) (2024)

Environmental and Molecular Mutagenesis 7 citations DOI OpenAlex
Abstract 2440: Cancer driver mutations as quantitative biomarkers of cancer risk interspecies analyses using CarcSeq (2024)

Cancer Research DOI OpenAlex
Interpretation of in vitro concentration‐response data for risk assessment and regulatory decision‐making: Report from the 2022 <scp>IWGT</scp> quantitative analysis expert working group meeting (2023)

Environmental and Molecular Mutagenesis 8 citations DOI OpenAlex
Error-corrected next generation sequencing – Promises and challenges for genotoxicity and cancer risk assessment (2023)

Mutation Research/Reviews in Mutation Research 64 citations DOI OpenAlex
Interpretation of In Vitro Concentration-Response Data for Risk Assessment and Regulatory Decision-making: Report from 2022 IWGT Quantitative Analysis Expert Working Group Meeting (2023)

2 citations DOI OpenAlex
Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing (2023)

Nature Reviews Drug Discovery 44 citations DOI OpenAlex
Launching the “Projections” series in mutation research reviews with a special issue on next generation sequencing (2021)

Mutation Research/Reviews in Mutation Research DOI OpenAlex
Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia (2021)

Toxicological Sciences 7 citations DOI OpenAlex
A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency (2021)

Genome biology 61 citations DOI OpenAlex